SenesTech (NASDAQ: SNES) Gains Investor Confidence Amidst Strong Pilot Results and Revenue Growth

• Glenbrook Capital Management significantly increased its stake in SenesTech, now owning over 30% and advocating for strategic enhancements.
• SenesTech demonstrated robust financial performance with 40% third-quarter revenue growth and a record $1.10 million in quarterly revenue.
• The Chicago pilot program for SenesTech's Evolve Rat Birth Control product showed remarkable efficacy, including an 88% drop in rat activity and a 36% reduction in rodent-related 311 calls.

SenesTech (NASDAQ: SNES), a leading innovator in rodent birth control products, has attracted significant investor attention. Glenbrook Capital Management, already a 10% owner, further solidified its position by purchasing 376,552 shares of common stock at $0.70 per share on October 19, 2026. This strategic investment brings Glenbrook's total holdings to approximately 2.06 million shares, signaling strong confidence in the company's future.

Glenbrook Capital Management now asserts ownership of more than 30% of SenesTech’s outstanding common shares. In an October 19 letter to board chairman Matthew Szot, highlighted by PR Newswire, Glenbrook advocated for a refined market strategy and enhanced focus on capitalization to unlock greater company value for the pest control solutions provider.

Highlighting SenesTech's robust financial performance, Glenbrook also noted a significant 40% third-quarter revenue growth and an impressive $4.00 million revenue run rate. While a run rate projects annual sales based on recent performance, SenesTech independently announced a record quarterly revenue milestone of $1.10 million, underscoring its strong market traction.

Further bolstering its market position, SenesTech reported compelling results from a 12-month Chicago pilot of its innovative Evolve Rat Birth Control product. The program demonstrated an impressive 88% drop in average rat activity intensity and an 82% reduction in monitoring locations with detectable activity, as highlighted by GlobeNewswire. Notably, rodent-related 311 calls in the deployment area decreased by 36%, contrasting with a rise in citywide calls. The Evolve solution now extends its reach to six Chicago-area special service areas and wards, showcasing its effectiveness in urban pest control.

From a stock valuation perspective, SenesTech currently trades at 1.56 times sales, a key metric for assessing its value relative to revenue. The company's robust current ratio of 6.78 signifies strong liquidity, with current assets being 6.78 times its current liabilities. Furthermore, a healthy debt-to-equity ratio of 0.43 reflects a manageable level of financial leverage.